Mixed Quarter for Haemonetics - Analyst Blog
February 01 2013 - 4:50AM
Zacks
Haemonetics
Corporation (HAE) reported net income of $9.9 million or
earnings of 19 cents per share in the third quarter of fiscal 2013,
down 46% and 47% year over year, respectively. However, after
taking into account certain one-time items, adjusted earnings came
in at 50 cents per share, surpassing both the Zacks Consensus
Estimate of 47 cents and the year-ago quarter’s adjusted earnings
of 43 cents per share.
Revenues increased 29% year over
year (up 31% at CER) to $247.4 million, missing the Zacks Consensus
Estimate of $252 million. After taking into account the recently
acquired whole blood business from Pall
Corporation (PLL), the company recorded organic net
revenue of $192.5 million, up 1% year over year.
Revenues from the US and the
international market increased 36.1% and 23.2% to $125.4 million
and $112.0 million, respectively. Barring North Americaand
Japan,where organic revenues declined a respective 1% and 2% year
over year, growth was recorded across the other regions namely,
Asia (11%) and Europe(2%).
Revenue
Details
Haemonetics earns about 86% of its
revenues from the sale of disposables – plasma, blood center, and
hospital disposables. Revenues from these segments stood at $68.1
million, (down 1.4% year over year), $111.8 million (up 97.7%) and
$32.8 million (up 6.4%), respectively. The rest of the revenue was
derived from software solutions and equipment, which recorded
respective sales of $16.0 million (up 1% year over year) and $18.7
million (down 1.1%).
Haemonetics expects its plasma
business growth to be at the low end of its earlier projection of
4−6% growth in fiscal 2013. Within blood center disposables,
revenues from platelets disposables inched up 2% to $45.1 million
while red cell disposables were down 3% at $11.8 million.
Subsequent to the completion of the acquisition, whole blood was
inducted in the company’s portfolio in the earlier quarter and
recorded $54.9 million of sales in the reported quarter. The
company restated that this business is expected to gross $135−$145
million in fiscal 2013.
Platelet revenues continued to
benefit from strong sales in emerging markets. The decline in red
cell disposables was a result of the company’s focus on penetration
of the Impact accounts to advance blood management solutions. The
company expects its blood center business to remain flat
organically in fiscal 2013 (0−2% expected previously).
OrthoPAT (orthopedic perioperative
autotransfusion system)was down 9% year over year at $7.1 million.
However, the company expects the impending launch of its new
OrthoPAT Advance system in thefirst half of fiscal 2014 followed by
its recent 510(k) approval will start driving growth in OrthoPAT in
fiscal 2014.
Revenues from Surgical disposables
and Diagnostics increased 9% to $56.0 million and 19% to $6.8
million, respectively. While the former benefited from the
6th consecutive quarter of growth from the Cell Saver
Elite, growth of the Diagnostics business resulted from the
company's Impact initiative that benefited the TEG
Thrombelastograph Hemostasis Analyzer business. Strong sales of
Cell Saver Elite and TEG equipments signify growth in disposables
revenue in the forthcoming quarter. During the reported quarter,
TEG disposables sales increased over 50% in China.
The company expects its hospital
business to grow 11% (versus 12−15% expected previously) in fiscal
2013, which will be supported by growth in surgical, diagnostics
and disposables, mostly in emerging markets.
Margin Trends
The company reported a 29.9%
increase in adjusted gross profit to $124.6 million accompanied by
20 basis points (bps) expansion in gross margin to 50.4% during the
quarter. Margin improvement in the core business offset the impact
of revenue mix toward low-margin whole blood disposables.
Despite an increase in adjusted
operating expenses (up 26.4% to $83.7 million), the adjusted
operating margin expanded 100 bps to 16.5%. The rise in operating
expenses was due to inclusion of $14 million in the new whole blood
collection business andinvestments in global growth initiatives,
emerging markets and infrastructure development.
Shareholder
Rewards
Haemonetics completed its earlier
approved a two-for-one split in the form of a 100% stock dividend.
On a post-split basis, the company continued with its stock buyback
program and repurchased 393.100 shares for $40.24 per share. The
board of directors had previously approved the repurchase of up to
$50 million of shares during the remainder of fiscal 2013.
Outlook
Haemonetics now expects its organic
revenue to grow 4%, at the low end of its earlier growth forecast
of 4−6% for fiscal 2013, resulting in total revenue of $888–$898
million(earlier guidance was $890−$915 million), up 22−23% (23−26%)
year over year. Adjusted EPS guidance of $1.65–$1.70was
reiterated.
The company still expects to report
adjusted gross margin in the range of 50−51% with adjusted
operating income of $127−$130 million. The outlook for gross margin
takes into account the low-margin whole blood product line.
Besides, free cash flow is still expected to be around $80 million
($80 million).
The company also reiterated its
outlook for fiscal 2014, with organic revenue growth of 5–7% (more
than $1 billion of total revenue) resulting in adjusted EPS of
$1.95–$2.05(representing 20% growth over the expected EPS for
fiscal 2013.
Recommendation
Haemonetics reported a mixed
quarter with earnings beating the Zacks Consensus Estimate and
revenues falling short. The improvement in margins during the
quarter was encouraging. Low global penetration and positive demand
dynamics provide an encouraging long-term thesis for investing in
the blood processing and supply chain management industry.
The stock holds a Zacks Rank #2
(Buy). Other medical device stocks worth a look are Cantel
Medical Corp. (CMN) and ResMed Inc.
(RMD). Both the stocks carry a Zacks Rank #1 (Strong Buy).
CANTEL MED CORP (CMN): Free Stock Analysis Report
HAEMONETICS CP (HAE): Free Stock Analysis Report
PALL CORP (PLL): Free Stock Analysis Report
RESMED INC (RMD): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
Cantel Medical (NYSE:CMD)
Historical Stock Chart
From Jun 2024 to Jul 2024
Cantel Medical (NYSE:CMD)
Historical Stock Chart
From Jul 2023 to Jul 2024